Immune Responses Of Elderly Persons 4 Years After Receiving A Live Attenuated Varicella Vaccine
Annually, for 4 years after a live attenuated varicella-zoster virus (VZV) vaccine was administered to 202 elderly (55 to >87 years old) VZV-immune persons, the immune response of vaccinees was evaluated. Anti-VZV antibody levels were enhanced by vaccination for just 1 year. However, VZV-specific...
Gespeichert in:
| Veröffentlicht in: | The Journal of infectious diseases 1994-09, Vol.170 (3), p.522-526 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 526 |
|---|---|
| container_issue | 3 |
| container_start_page | 522 |
| container_title | The Journal of infectious diseases |
| container_volume | 170 |
| creator | Levin, Myron J. Murray, Martha Zerbe, Gary O. Jo White, C. Hayward, Anthony R. |
| description | Annually, for 4 years after a live attenuated varicella-zoster virus (VZV) vaccine was administered to 202 elderly (55 to >87 years old) VZV-immune persons, the immune response of vaccinees was evaluated. Anti-VZV antibody levels were enhanced by vaccination for just 1 year. However, VZV-specific proliferating T cells in peripheral blood were increased in frequency from 1 in 68,000 to 1 in 40,000 at 1 year; VZV-responding T cells were still 1 in 51,000 4 years after vaccination. The calculated half-life of this enhanced immunity was 54 months. Age had little effect on response to the vaccine, but larger doses were associated with longer duration of enhanced immunity. Immunity in ∼10%-15% of vaccinees, independent of dose, failed to increase with the vaccine. This might complicate the use of this vaccine for prevention or attenuation of herpes zoster in the elderly. |
| doi_str_mv | 10.1093/infdis/170.3.522 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_76687235</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>30132677</jstor_id><sourcerecordid>30132677</sourcerecordid><originalsourceid>FETCH-LOGICAL-c385t-bd7fc1a48be1731120bfc27a8658ecf8d6effa1ab661e02e28e5d4e4589b7b573</originalsourceid><addsrcrecordid>eNqFkMtvEzEQxi0EKqFw54LkE7dNx_b6sceoKk1FpCL6EHCxvN4xctlHsHer9r9nQ6Jw5OSRv2--mfkR8p7BkkElzmIfmpjPmIalWErOX5AFk0IXSjHxkiwAOC-YqarX5E3ODwBQCqVPyIkBrTVUC2Kvum7qkX7FvB36jJleB3rRNpjaZ_oFU54_aUm_o0uZrsKIabZ6jI-x_0lXdBMfka7GEfvJjdjQe5eix7Z1c-V97PEteRVcm_Hd4T0ld58ubs_Xxeb68up8tSm8MHIs6kYHz1xpamRaMMahDp5rZ5Q06INpFIbgmKvnwxA4coOyKbGUpqp1LbU4JR_3uds0_J4wj7aL-e8mPQ5Ttlopo7mQ_zUypQVAtUuEvdGnIeeEwW5T7Fx6tgzsDr7dw7czfCvsDH9u-XDInuoOm2PDgfY__SGPQzrKApjgSu9GFns95hGfjrpLv-y8lZZ2_e2HLW9u4TOs760QfwDJxZoT</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16730097</pqid></control><display><type>article</type><title>Immune Responses Of Elderly Persons 4 Years After Receiving A Live Attenuated Varicella Vaccine</title><source>Jstor Complete Legacy</source><source>MEDLINE</source><creator>Levin, Myron J. ; Murray, Martha ; Zerbe, Gary O. ; Jo White, C. ; Hayward, Anthony R.</creator><creatorcontrib>Levin, Myron J. ; Murray, Martha ; Zerbe, Gary O. ; Jo White, C. ; Hayward, Anthony R.</creatorcontrib><description>Annually, for 4 years after a live attenuated varicella-zoster virus (VZV) vaccine was administered to 202 elderly (55 to >87 years old) VZV-immune persons, the immune response of vaccinees was evaluated. Anti-VZV antibody levels were enhanced by vaccination for just 1 year. However, VZV-specific proliferating T cells in peripheral blood were increased in frequency from 1 in 68,000 to 1 in 40,000 at 1 year; VZV-responding T cells were still 1 in 51,000 4 years after vaccination. The calculated half-life of this enhanced immunity was 54 months. Age had little effect on response to the vaccine, but larger doses were associated with longer duration of enhanced immunity. Immunity in ∼10%-15% of vaccinees, independent of dose, failed to increase with the vaccine. This might complicate the use of this vaccine for prevention or attenuation of herpes zoster in the elderly.</description><identifier>ISSN: 0022-1899</identifier><identifier>EISSN: 1537-6613</identifier><identifier>DOI: 10.1093/infdis/170.3.522</identifier><identifier>PMID: 8077709</identifier><language>eng</language><publisher>United States: The University of Chicago Press</publisher><subject>Age Factors ; Aged ; Aged, 80 and over ; Antibodies ; Antibodies, Viral - blood ; Antigens ; Chickenpox Vaccine ; Enzyme-Linked Immunosorbent Assay - methods ; Follow-Up Studies ; Herpes zoster ; Human herpesvirus 3 ; Humans ; Immunity ; Immunoglobulin G - blood ; Lesions ; Lymphocyte Activation ; Major Articles ; Middle Aged ; Older adults ; Sex Characteristics ; Sex Factors ; T-Lymphocytes - immunology ; Time Factors ; Transponders ; Vaccination ; Vaccines, Attenuated - adverse effects ; Vaccines, Attenuated - immunology ; Varicella zoster encephalitis ; varicella-zoster virus ; Viral Vaccines - adverse effects ; Viral Vaccines - immunology</subject><ispartof>The Journal of infectious diseases, 1994-09, Vol.170 (3), p.522-526</ispartof><rights>Copyright 1994 The University of Chicago</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c385t-bd7fc1a48be1731120bfc27a8658ecf8d6effa1ab661e02e28e5d4e4589b7b573</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/30132677$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/30132677$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,776,780,799,27901,27902,57992,58225</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8077709$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Levin, Myron J.</creatorcontrib><creatorcontrib>Murray, Martha</creatorcontrib><creatorcontrib>Zerbe, Gary O.</creatorcontrib><creatorcontrib>Jo White, C.</creatorcontrib><creatorcontrib>Hayward, Anthony R.</creatorcontrib><title>Immune Responses Of Elderly Persons 4 Years After Receiving A Live Attenuated Varicella Vaccine</title><title>The Journal of infectious diseases</title><addtitle>J Infect Dis</addtitle><description>Annually, for 4 years after a live attenuated varicella-zoster virus (VZV) vaccine was administered to 202 elderly (55 to >87 years old) VZV-immune persons, the immune response of vaccinees was evaluated. Anti-VZV antibody levels were enhanced by vaccination for just 1 year. However, VZV-specific proliferating T cells in peripheral blood were increased in frequency from 1 in 68,000 to 1 in 40,000 at 1 year; VZV-responding T cells were still 1 in 51,000 4 years after vaccination. The calculated half-life of this enhanced immunity was 54 months. Age had little effect on response to the vaccine, but larger doses were associated with longer duration of enhanced immunity. Immunity in ∼10%-15% of vaccinees, independent of dose, failed to increase with the vaccine. This might complicate the use of this vaccine for prevention or attenuation of herpes zoster in the elderly.</description><subject>Age Factors</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antibodies</subject><subject>Antibodies, Viral - blood</subject><subject>Antigens</subject><subject>Chickenpox Vaccine</subject><subject>Enzyme-Linked Immunosorbent Assay - methods</subject><subject>Follow-Up Studies</subject><subject>Herpes zoster</subject><subject>Human herpesvirus 3</subject><subject>Humans</subject><subject>Immunity</subject><subject>Immunoglobulin G - blood</subject><subject>Lesions</subject><subject>Lymphocyte Activation</subject><subject>Major Articles</subject><subject>Middle Aged</subject><subject>Older adults</subject><subject>Sex Characteristics</subject><subject>Sex Factors</subject><subject>T-Lymphocytes - immunology</subject><subject>Time Factors</subject><subject>Transponders</subject><subject>Vaccination</subject><subject>Vaccines, Attenuated - adverse effects</subject><subject>Vaccines, Attenuated - immunology</subject><subject>Varicella zoster encephalitis</subject><subject>varicella-zoster virus</subject><subject>Viral Vaccines - adverse effects</subject><subject>Viral Vaccines - immunology</subject><issn>0022-1899</issn><issn>1537-6613</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1994</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkMtvEzEQxi0EKqFw54LkE7dNx_b6sceoKk1FpCL6EHCxvN4xctlHsHer9r9nQ6Jw5OSRv2--mfkR8p7BkkElzmIfmpjPmIalWErOX5AFk0IXSjHxkiwAOC-YqarX5E3ODwBQCqVPyIkBrTVUC2Kvum7qkX7FvB36jJleB3rRNpjaZ_oFU54_aUm_o0uZrsKIabZ6jI-x_0lXdBMfka7GEfvJjdjQe5eix7Z1c-V97PEteRVcm_Hd4T0ld58ubs_Xxeb68up8tSm8MHIs6kYHz1xpamRaMMahDp5rZ5Q06INpFIbgmKvnwxA4coOyKbGUpqp1LbU4JR_3uds0_J4wj7aL-e8mPQ5Ttlopo7mQ_zUypQVAtUuEvdGnIeeEwW5T7Fx6tgzsDr7dw7czfCvsDH9u-XDInuoOm2PDgfY__SGPQzrKApjgSu9GFns95hGfjrpLv-y8lZZ2_e2HLW9u4TOs760QfwDJxZoT</recordid><startdate>19940901</startdate><enddate>19940901</enddate><creator>Levin, Myron J.</creator><creator>Murray, Martha</creator><creator>Zerbe, Gary O.</creator><creator>Jo White, C.</creator><creator>Hayward, Anthony R.</creator><general>The University of Chicago Press</general><general>University of Chicago Press</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>19940901</creationdate><title>Immune Responses Of Elderly Persons 4 Years After Receiving A Live Attenuated Varicella Vaccine</title><author>Levin, Myron J. ; Murray, Martha ; Zerbe, Gary O. ; Jo White, C. ; Hayward, Anthony R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c385t-bd7fc1a48be1731120bfc27a8658ecf8d6effa1ab661e02e28e5d4e4589b7b573</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1994</creationdate><topic>Age Factors</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antibodies</topic><topic>Antibodies, Viral - blood</topic><topic>Antigens</topic><topic>Chickenpox Vaccine</topic><topic>Enzyme-Linked Immunosorbent Assay - methods</topic><topic>Follow-Up Studies</topic><topic>Herpes zoster</topic><topic>Human herpesvirus 3</topic><topic>Humans</topic><topic>Immunity</topic><topic>Immunoglobulin G - blood</topic><topic>Lesions</topic><topic>Lymphocyte Activation</topic><topic>Major Articles</topic><topic>Middle Aged</topic><topic>Older adults</topic><topic>Sex Characteristics</topic><topic>Sex Factors</topic><topic>T-Lymphocytes - immunology</topic><topic>Time Factors</topic><topic>Transponders</topic><topic>Vaccination</topic><topic>Vaccines, Attenuated - adverse effects</topic><topic>Vaccines, Attenuated - immunology</topic><topic>Varicella zoster encephalitis</topic><topic>varicella-zoster virus</topic><topic>Viral Vaccines - adverse effects</topic><topic>Viral Vaccines - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Levin, Myron J.</creatorcontrib><creatorcontrib>Murray, Martha</creatorcontrib><creatorcontrib>Zerbe, Gary O.</creatorcontrib><creatorcontrib>Jo White, C.</creatorcontrib><creatorcontrib>Hayward, Anthony R.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Levin, Myron J.</au><au>Murray, Martha</au><au>Zerbe, Gary O.</au><au>Jo White, C.</au><au>Hayward, Anthony R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immune Responses Of Elderly Persons 4 Years After Receiving A Live Attenuated Varicella Vaccine</atitle><jtitle>The Journal of infectious diseases</jtitle><addtitle>J Infect Dis</addtitle><date>1994-09-01</date><risdate>1994</risdate><volume>170</volume><issue>3</issue><spage>522</spage><epage>526</epage><pages>522-526</pages><issn>0022-1899</issn><eissn>1537-6613</eissn><abstract>Annually, for 4 years after a live attenuated varicella-zoster virus (VZV) vaccine was administered to 202 elderly (55 to >87 years old) VZV-immune persons, the immune response of vaccinees was evaluated. Anti-VZV antibody levels were enhanced by vaccination for just 1 year. However, VZV-specific proliferating T cells in peripheral blood were increased in frequency from 1 in 68,000 to 1 in 40,000 at 1 year; VZV-responding T cells were still 1 in 51,000 4 years after vaccination. The calculated half-life of this enhanced immunity was 54 months. Age had little effect on response to the vaccine, but larger doses were associated with longer duration of enhanced immunity. Immunity in ∼10%-15% of vaccinees, independent of dose, failed to increase with the vaccine. This might complicate the use of this vaccine for prevention or attenuation of herpes zoster in the elderly.</abstract><cop>United States</cop><pub>The University of Chicago Press</pub><pmid>8077709</pmid><doi>10.1093/infdis/170.3.522</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-1899 |
| ispartof | The Journal of infectious diseases, 1994-09, Vol.170 (3), p.522-526 |
| issn | 0022-1899 1537-6613 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_76687235 |
| source | Jstor Complete Legacy; MEDLINE |
| subjects | Age Factors Aged Aged, 80 and over Antibodies Antibodies, Viral - blood Antigens Chickenpox Vaccine Enzyme-Linked Immunosorbent Assay - methods Follow-Up Studies Herpes zoster Human herpesvirus 3 Humans Immunity Immunoglobulin G - blood Lesions Lymphocyte Activation Major Articles Middle Aged Older adults Sex Characteristics Sex Factors T-Lymphocytes - immunology Time Factors Transponders Vaccination Vaccines, Attenuated - adverse effects Vaccines, Attenuated - immunology Varicella zoster encephalitis varicella-zoster virus Viral Vaccines - adverse effects Viral Vaccines - immunology |
| title | Immune Responses Of Elderly Persons 4 Years After Receiving A Live Attenuated Varicella Vaccine |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T18%3A24%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immune%20Responses%20Of%20Elderly%20Persons%204%20Years%20After%20Receiving%20A%20Live%20Attenuated%20Varicella%20Vaccine&rft.jtitle=The%20Journal%20of%20infectious%20diseases&rft.au=Levin,%20Myron%20J.&rft.date=1994-09-01&rft.volume=170&rft.issue=3&rft.spage=522&rft.epage=526&rft.pages=522-526&rft.issn=0022-1899&rft.eissn=1537-6613&rft_id=info:doi/10.1093/infdis/170.3.522&rft_dat=%3Cjstor_proqu%3E30132677%3C/jstor_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=16730097&rft_id=info:pmid/8077709&rft_jstor_id=30132677&rfr_iscdi=true |